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Abstract: Autism is a brain disorder involving social, memory, and learning deficits, that 
normally develops prenatally or early in childhood. Frustratingly, many research dollars 
have as yet failed to identify the cause of autism. While twin concordance studies indicate 
a strong genetic component, the alarming rise in the incidence of autism in the last three 
decades suggests that environmental factors play a key role as well. This dichotomy can be 
easily explained if we invoke a heritable epigenetic effect as the primary factor. 
Researchers are just beginning to realize the huge significance of epigenetic effects taking 
place during gestation in influencing the phenotypical expression. Here, we propose the 
novel hypothesis that sulfates deficiency in both the mother and the child, brought on 
mainly by excess exposure to environmental toxins and inadequate sunlight exposure to the 
skin, leads to widespread hypomethylation in the fetal brain with devastating 
consequences. We show that many seemingly disparate observations regarding serum 
markers, neuronal pathologies, and nutritional deficiencies associated with autism can be 
integrated to support our hypothesis. 
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1. Introduction 
Autism, and, more generally, autism spectrum disorder (ASD) is a developmental brain disorder 
involving social, cognitive, and memory deficits, whose incidence rates continue to climb unabated. 
The most recent estimate from the United States Centers for Disease Control now places the incidence 
rate in boys, who are affected far more often than girls, at one in 54 [1], with an overall rate among 
both genders of one in 88. Just being a twin, whether monozyotic or dizygotic, is a risk factor for 
autism [2]. This suggests that a nutritional deficiency in utero could be a factor, since twins would 
place twice the demand on any nutritional element. Thus, it supports the concept that epigenetic factors 
during gestation may be at play.  
While many different markers have been observed to be abnormal in association with autism, 
reduced levels of plasma sulfate and subsequent reduced sulfation capacity are among the most 
consistent findings in autism research [3]. A recent interest in sulfated glycosaminoglycans (GAGS) 
has spurred investigations highlighting the importance of sulfate in the developing brain [4]. It is 
proposed here that sulfate depletion, caused by a combination of various environmental factors and 
genetic predispositions, is an important contributor to the development of ASD, and that epigenetics 
plays an important role in readjusting the phenotypical expression to cope with a sulfate deficiency. 
The idea that impaired sulfate metabolism is a key factor in autism is not new [5–7]. An excellent 
review chapter [6] discusses several abnormal factors related to sulfate chemistry that have been found 
in association with autism. Observed serum imbalances include low plasma levels of free sulfate, 
abnormally high ratios of plasma cysteine to sulfate, and high loss of sulfite, sulfate and thiosulfate 
through the kidneys, as well as reduced levels of urinary thiocyanate [6]. Additionally, many sulfate-
dependent neurodevelopmental processes have been found to be defective in association with autism. 
Neonatal development depends critically upon sulfate for myelination in the brain and for the 
development of perineuronal nets formed from chondroitin sulfate, which modulate GABAergic 
inhibitory signaling. Both the Purkinje cells in the cerebellum and the GABAergic cells in the 
hippocampus depend on chondroitin sulfate for ion exchange. The maturing of dendrites depends upon 
heparan sulfate proteoglycans, and impaired dendritic maturity is a characteristic feature of brains at 
autopsy for individuals with autism. 
DNA methylation is increasingly recognized as an important regulatory mechanism during 
development [8]. Dramatic methylation changes take place during early embryonic development, and, 
in fact, methyltransferase-deficient mice produce nonviable embryos. Genome-wide demethylation 
takes place at the cavitation stage, and the reestablishment of appropriate tissue-specific methylation 
patterns takes place as the embryo matures. It is logical that insufficient supply of methyl donors would 
lead to hypomethylation of DNA, and that this would impact development in unpredictable ways. 
It has been proposed that impaired methylation capacity during development may play a role in 
autism [9–13], and this is consistent with the observed deficiencies in the transsulfuration pathways, 
which are intimately connected with the methylation pathways, through the common substrate, 
methionine, an essential amino acid [14]. In [13], on the basis of relevant biomarkers, a link is 
suggested between increased oxidative stress and impaired methylation capacity in autism. The early 
embryo has a critical need for methylation associated with selective gene silencing and activation 
during differentiation. It has recently been determined that methylation of the coding regions of DNA 
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encodes activation whereas methylation of the promoter regions encodes deactivation [9]. Since 
methionine is an important source of methyl groups for methylation, deficiencies in methionine 
translate into reduced methylation capacity, and therefore impaired activation and deactivation of 
tissue-specific genes. Such deficiencies can arise directly from oxidative stress induced by exposure to 
environmental toxins, particularly in the context of a genetic predisposition [10]. 
Recent research on 80 autistic children, compared to 75 age-matched controls, demonstrated that 
children with autism had a serum ratio of S-adenosylmethione (SAM) to S-adenosylhomoycysteine 
(SAH) (SAM/SAH ratio) that was only 50% of that of the controls. A similar result was found in [12], 
where children with autism were found to have decreased blood levels of glutathione, glutathione 
peroxidase, methionine, and cysteine, as well as increased concentrations of oxidized glutathione (GSSG). 
Significantly, in [15], it was shown that even the parents of autistic children exhibit a metabolic profile 
reflecting reduced methylation capacity, associated with elevated homocysteine levels. Since 
homocysteine readily crosses the placental membrane [16], and since excess homocysteine is associated 
with DNA hypomethylation, likely due to inhibition of DNA methyltransferase by SAH [17–19], impaired 
methylation capacity in the mother would likely translate into impaired methylation capacity in the fetus. 
Different tissue types are associated with a unique signature of hypermethylated genes, leading to 
active gene expression of the proteins specifically needed by the particular tissue type. Recent research 
has begun to characterize the “methylome,” at least with respect to a small number of cell types. 
Particularly salient for our purposes is the functional subset of genes that are preferentially expressed 
through hypermethylation in neurons [9].  
Using hidden-Markov model (HMM) techniques to label partially methylated regions and 
distinguish these regions as highly methylated in neurons, these authors were able to genomically map 
a set of genes with distinct neuronal functions. They established that genes associated with cell 
adhesion, ion transport, cell-cell signaling, synaptic transmission, neuronal differentiation and nerve 
impulse transmission were differentially activated in neurons, when compared to lung fibroblasts and 
embryonic stem cells. Insufficient activation of these genes through impaired methylation would be 
expected to cause pathological neuronal expression as is observed in autism. 
In the remainder of this paper, we will first discuss the importance of sulfation in biology. We will 
then look specifically at the role of sulfate in the developing brain, focusing on serotonin and the 
glycosaminoglycans. We next turn our attention towards evidence of abnormal sulfate metablism in 
association with autism, including impaired sulfoconjugation capacity and increased sulfate excretion. 
We will then discuss available theories concerning possible causes of this impairment, including 
genetic effects and environmental effects. In particular, we will emphasize the effect of insufficient 
sunlight exposure to the skin and will argue that this issue goes beyond vitamin D3 deficiency. We 
further discuss how other known characteristics of children on the autism spectrum, such as 
gastrointestinal problems, increased androgen levels, and increased inflammation, can be explained by 
the sulfate deficit, and we will show that treatments aimed at repairing sulfate metabolism have shown 
some benefit. Finally, we will discuss the evidence for an epigenetic effect related to genomic 
hypomethylation in the fetus in association with autism. We conclude with a discussion section where 
we elaborate on our hypothesis and demonstrate how it can explain all of the complex factors 
associated with autism. Finally, we discuss simple lifestyle changes that could be implemented to 
address the problem. 
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2. The Importance of Sulfation 
Many diverse molecules throughout the body require sulfation. Some examples include xenobiotics, 
which are inactivated and made water soluble through sulfation (this facilitates their excretion); 
neurosteroids, hormones, and catchecholamines, which are also inactivated by sulfation (this can 
regulate the local expression of their active forms); and glycosaminoglycans, polysaccharide chains 
that are sulfated in a highly unique pattern, which serves to modulate the structure and function of the 
proteoglycans that make up the extracellular matrix. 
The universal sulfate donor for each of these reactions is 3’-phosphoadenosine 5’-phosphosulfate 
(PAPS). Synthesis of PAPS is the limiting factor in sulfation and involves a two-step reaction using 
inorganic sulfate as substrate, which consumes two ATP [20] molecules. PAPS availability is thus 
dependent on the availability of sulfate and ATP, and on the subsequent activity of two enzymes: ATP-
sulfurylase and APS-kinase. Factors which can decrease PAPS availability, thereby reducing the 
sulfation of biological molecules, include a low-sulfur diet and administration of xenobiotics such as 
acetaminophen which are processed for elimination through sulfation [20]. 
Along with PAPS, the process of sulfation requires a sulfotransferase (SULT) enzyme which is 
specific to the substrate [21]. There are five SULT families, each family targeting a different set of 
substrates. The various sulfotransferases are expressed in many tissues throughout the body, including 
the brain. SULT1 isoforms have been identified in the fetal brain, and it is clear that significant 
alterations in sulfotransferase activity take place during development, suggesting that sulfotransferases 
play a critical role in the development of the central nervous system. 
SULT1, which includes five subtypes, is the best known of the sulfotransferase families. The 
SULT1A class, which has been found in platelets, liver, breast, and gastrointestinal tract, as well as the 
brain [21], targets phenols and catchecholamines, while the SULT1B class targets thyroid hormones, 
the SULT1C’s target xenobiotics, and SULT1E’s target estrogenic steroids [22]. The SULT2 enzymes 
sulfonate cholesterol and the derived hydroxysteroids, such as pregnenolone, DHEA, and other 
neurosteroids. SULT3 catalyzes the formation of sulfamates, while SULT4 and SULT5 have not been 
fully characterized. 
The SULT1A subclass appears to be most relevant to autism. Indeed, a genetic link has been found 
between mutations in the SULT1A locus and autism [23–25]. Decreased expression of SULT1A in 
both platelets and the gastrointestinal tract has also been observed in individuals with ASD [7,21] 
along with increased levels of neurotransmitters and catechols, which are substrates for sulfation [26]. 
Since sulfate is the rate-limiting factor in the synthesis of PAPS as substrate for the sulfotransferase 
reactions, low sulfate levels and low SULT1A levels have the potential to invoke the same pathology. 
We hypothesize that decreased expression of SULT1A, possibly even through epigenetic mechanisms, 
may be protective in autism, by forcing potentially toxic metabolites to be processed via 
glucuronylation rather than sulfation [27], thus sparing sulfate from elimination, but increasing the 
likelihood of adverse reactions to environmental phenols. 
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3. Sulfate’s Role in the Developing Brain 
Sulfate is a vital nutrient required for proper development, and as such, normally flows in abundant 
supply from the mother to the fetus. The developing child receives sulfate from the mother through the 
placental villi and later through colostrum, the mother’s first milk [28]. Especially during the third 
trimester, renal reabsorption of inorganic sulfate increases in the mother, increasing serum sulfate 
levels. This causes an increase in inorganic sulfate concentrations in the mother’s amniotic fluid and an 
enrichment of cholesterol sulfate in the placental villi. It has been hypothesized that sulfation of 
cholesterol, making it amphiphilic, allows it to penetrate the placental barrier [29]. It also then 
becomes a potential source of sulfate to the fetus. Cholesterol sulfate levels in the villi rise 
dramatically throughout pregnancy. The concentration of cholesterol sulfate increases from 3.93 to 
18.35 to 23.75 pmol/mg dry mass over the course of the three trimesters, a six-fold increase from the 
first trimester to the third trimester [30]. During this same period, serum inorganic sulfate in the fetus 
is even higher than serum inorganic sulfate in the mother [20]. 
Within the brain, sulfate transporters are expressed most strongly in the cerebellum and the 
hippocampus, implying that these two regions carry out important processes requiring sulfate 
regulation [31]. Interestingly, both of these brain regions have been implicated in the pathogenesis of 
autism [32,33]. Sulfate may work in the brain through two major pathways: as an integral component 
of the extracellular matrix, and as a deactivator of many different neurotransmitters, including 
serotonin, dopamine, DHEA, and pregnenolone. 
3.1. Sulfation of Glycosaminoglycans 
One important use of sulfate in the body is to supply sulfate groups to the glycosaminoglycans 
(GAGS), sulfated sugar molecules on the cell surface that have recently been investigated as a crucial 
component in a number of processes, including cell-cell signaling, fibroblast growth factor (FGF) 
regulation, axon growth and guidance, and brain development [34–36]. In particular heparan sulfate 
progeoglycans (HSPGs) are essential for neurite outgrowth and connectivity between neurons and their 
target cells [35], and have been shown to be important in neurogenesis, axonal guidance, and synapse 
development [36]. HSPGs appeared very early in development in the animal kingdom, predating 
multicellular organisms and appearing simultaneously with the first nervous systems [37].  
Of special interest is a recent discovery that a postnatally induced heparan sulfate deficiency in the 
brain is capable of causing autistic behavior in mice, including impairments in social interaction, 
expression of stereotyped, repetitive behavior, and impairments in ultrasonic vocalization, all without 
causing detectable changes in cellular arrangement in the brain [38]. A deficiency in sulfate will cause 
a reduced supply of PAPS, which has been shown to reduce the sulfation of GAGS [20,39]. Since the 
sulfation of GAGS is very specific and highly regulated, reduced sulfation of these important 
molecules has the potential to cause serious problems. 
3.2. Sulfation of Serotonin 
A reduced supply of sulfate would likely impair the sulfation of serotonin, thus impairing its 
inactivation. Indeed, increased levels of serotonin were identified in 20–48% of children diagnosed 
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with autism and are one of the most consistently replicated biochemical findings in autism [3,40,41] 
Not only do increased levels of serotonin affect day-to-day brain functioning, but they also affect the 
development and outgrowth of serotonergic neurons, with increased levels of serotonin causing a loss 
of serotonin terminals in rat pups [42]. Increased serotonin during prenatal brain development has been 
shown to cause autistic symptoms in rats, including decreased social bonding, sensory hyper-
responsiveness, seizures and motor changes, and a loss of oxytocin-containing cells in the 
hypothalamus [43]. An increased risk to seizures [44] and deficits in oxytocin processing [45] have 
both been found in association with autism. 
Consistent with the idea that excess levels of serotonin are involved in the pathogenesis of autism is 
the fact that prenatal cocaine exposure, which increases serotonin, is heavily associated with autism at 
a rate of 11.4% [46]. A strong connection exists between autism and Smith-Lemli-Opitz Syndrome 
(SLOS), which is caused by a defect in the enzyme catalyzing the last step in cholesterol synthesis. 
Fifty three of those with SLOS develop autism [47], which might also be explained through serotonin, 
as cholesterol depletion has been shown to cause a loss of serotonin transporter (SERT) activity [48]. 
4. Findings of Abnormal Sulfate Metabolism in Autism 
As summarized in Figure 1, individuals with ASD have significantly lower plasma levels of bound 
sulfate, free sulfate, and the sulfur metabolites cysteine, taurine, and glutathione (GSH), and 
significantly higher levels of oxidized glutathione disulfide (GSSG) relative to controls [49]. The role 
of homocysteine warrants further study, as it has been reported to be increased in autism [50] as well 
as decreased [51]. A decrease in homocysteine might reflect a generic deficiency in sulfur-containing 
amino acids, whereas an increase could reflect impairment in the pathway that regenerates methionine 
from homocysteine, which depends on both folate and cobalamin (vitamin B12) as cofactors (see 
Figure 1). Both free sulfate and reduced glutathione, which are depleted in autism, are important for 
detoxification, and lower levels of these metabolites are associated with oxidative stress, which could 
explain why inflammation biomarkers [44] and antioxidant biomarkers [5] tend to be higher in 
association with autism. 
4.1. Evidence of Impaired Sulfoconjugation Capacity 
Individuals diagnosed with ASD tend to have impaired sulfoconjugation capacity, which manifests 
as a difficulty in metabolizing various compounds, especially phenolic amines—dopamine, tyramine, 
and serotonin—which function as neurotransmitters [52,53], and which are inactivated through 
sulfation by SULT1A, as previously discussed. 
4.2. Evidence of Increased Sulfate Excretion: Impairments in the Sodium Sulfate Cotransporter 
In [49], it was found that children diagnosed with autism have on average serum sulfate levels that 
are reduced to 33% of the levels found in controls. These abnormally low levels of free sulfate can be 
explained in part by reduced resorption of inorganic sulfate in the kidneys. Normally, the level of 
sulfate in the body is tightly regulated by membrane transport proteins in the renal proximal tubule, 
which include the sodium sulfate cotransporter NaSi-1 [54]. However, children diagnosed with autism 
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were found to have high urinary sulfate in addition to low plasma sulfate levels [7], suggesting that, in 
these individuals, the process of inorganic sulfate uptake and retention may have gone awry. 
Interestingly, the resorption of sulfate ions depends on the presence of sulfated proteins in the renal 
proximal tubule, so that, as sulfate levels decrease, the resorption of sulfate may decrease in a positive 
feedback loop [7]. 
Figure 1. The methylation and transsulfuration pathways, and observed impairments in 
association with autism. Diagram Sources: Alberti et al. [1]; Klaassen and Boles [2]; van 
der Kraan et al. [3]; Waring and Klovrza [4]. 
 
5. Potential Causes of Abnormal Sulfate Metabolism 
A decreased availability of sulfate can arise in the child during critical periods of brain development 
through a combination of genetic and environmental factors which can act prenatally (through the 
mother) or postnatally (directly on the child). The relationship between genetic mutations and autism is 
complex, but it has been proposed that an interaction between multiple susceptibility alleles and 
environmental factors could create a metabolic imbalance leading to autism [55], and we suggest that 
the common element among many of these genetic factors could be impaired sulfate metabolism. 
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5.1. Genetic Factors 
While genetic links with autism remain relatively weak and elusive, there are several genotypic 
differences involving sulfate metabolism and heparan sulfate production which are related to autism. 
These include variants in the components necessary for the methionine synthase reaction (see Figure 
1), sulfotransferase enzymes and molecules which show affinity for heparan sulfate. 
5.1.1. Methionine Synthase Reaction  
There are two routes for the metabolism of homocysteine in the body, the first of which leads to 
methionine through the methionine synthase reaction, and the second of which leads to cystathionine, 
catalyzed by cystathionine beta synthase (see Figure 1). The methionine synthase route enables 
methylation, while the cystathionine route protects from oxidation. Thus, low methionine levels will 
lead to reduced methylation and low cysathionine levels will lead to increased oxidative stress. Due to 
the fact that the methionine synthase reaction relies on B12, folate, and the reduced folate carrier, a lack 
of any one of these components will ultimately impair methylation. Zinc deficiency may also play a role. 
Several genetic variants associated with the conversion of homocysteine to methionine have been 
associated positively with increased risk for autism, including the genes involved in the transport of 
folate and the transport of B12. Methionine synthase, a B12 dependent enzyme, catalyzes a methyl 
transfer from N5-methyltetrahydrofolate to homocysteine using a zinc ion to activate the homocysteine 
substrate [56]. This reaction is also dependent on the oxidative state of its surroundings, with increased 
oxidation leading to decreased methionine synthase activity, directing production of homocysteine 
away from methionine and towards cystathionine [10]. This will help to alleviate the oxidative burden 
through the metabolism of cystathionine to reduced glutathione, as illustrated in Figure 2 [57], but will 
decrease the bioavailability of methyl groups. 
In order for the methionine synthase reaction to occur, reduced folate must be present inside the 
cell. Reduced folates are taken up by cells in a tightly regulated process governed by the reduced folate 
carrier (RFC) [58]. The RFC1 G allele, which is associated with impaired cellular uptake of folate 
[59], is overrepresented in children with autism. When compared with the AA genotype, the RFC-1 
GA or GG genotypes conferred twice the risk for autism [55]. 
Another gene involved in the transport of folate is methyltetrahydrofolate reductase (MTHFR). The 
MTHFR 677T allele, which is associated with reduced synthesis of metabolically active folate, also 
confers a higher susceptibility to autism, especially when paired with the RFC1 G allele. In fact, a 
combination of the RFC-1 80GG allele and the MTHFR 677CT genotype was found to increase the 
risk of autism three fold [55]. Overall, these data seem to support the idea that a genetic tendency 
toward a folate deficiency induced by impaired folate transport may alter methionine metabolism and 
cause a predisposition towards autism. 
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Figure 2. Sulfoconjugation of important metabolites. Metabolites present in excess in 
autism are highlighted in orange. 
 
Interestingly, further studies report that a polymorphism in the reduced folate carrier (RFC) in the 
mother is even more strongly associated with autism than a polymorphism in the child [60]. In the 
same study, elevated homocysteine, adenosine, and S-adenosyl homocysteine were also noted as risk 
factors in the mother.  
This suggests that the consequence of less effective methionine metabolism might be more relevant 
during the period when the fetus is developing in utero. Given that hyperhomocysteinemia, along with 
reduced levels of B12 and folate, is associated with obesity [61], this might help to explain the 
association between obesity in the mother and autism risk in the child [62]. 
Along with folate, cobalamin is also a critical cofactor in the methionine synthase reaction. One 
protein of interest in this process is transcobalamin II (TCN2), the transport protein which mediates the 
cellular uptake of B12 [63]. In this case, the TCN2776GG variant, which has a decreased binding 
affinity for B12, reduces its cellular uptake. This allele was found to increase the risk of autism 1.7-fold 
[55]. Indeed, it has been observed that B12 deficiency is associated with developmental regression that 
in many ways parallels the observed pathology associated with autism [64]. 
 hydrolyzes homocysteine thiolactone [65], thus participating in its conversion to sulfate [66]. An 
association between reduced PON1 activity and autism in the United States was reported in [67]. 
Factors which might have contributed to this deficiency that were considered included excess dietary 
high fructose corn syrup (HFCS), insufficient dietary magnesium, and exposure to mercury. An 
association between PON1 deficiency and HFCS exposure has been confirmed in rats [68]. 
Overall, low methionine levels are observed in many children diagnosed with autism. As oxidative 
stress reduces methionine synthase activity [57], a combination of genetically impaired folate 
transport, B12 transport, and oxidative stress might work in tandem to produce this outcome. 
5.1.2. Sulfotransferase Enzymes 
Further along in the transsulfuration pathway, the sulfotransferase enzymes act to add sulfate 
groups to glycosaminoglycans, such as heparan sulfate, which among their many other roles are crucial 
components of neural development. Interestingly, two different sulfotransferase enzymes, phenol-
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sulfotransferase-P and heparan sulfate (glucosamine) 3-O-sulfotransferase 5 (HS2ST5), have been 
implicated in autism. In [53], it was found that all 40 children with autism who were tested showed 
decreased levels of the enzyme, phenolsulfotransferase-P (PST). Impaired PST function could lead to 
impaired elimination of the phenols found in food sources. 
Finally, in a study done on two cohorts of European ancestry [69], a genetic association has been 
found between autism and a variant of the heparan sulfate (glucosamine) 3-O-sulfotransferase 5 
(HS3ST5) gene. Heparan sulfate glucosamine 3-O-sulfotransferase catalyzes the transfer of a sulfate 
group from PAPS to [heparan sulfate]-glucosamine, forming [heparan sulfate]-glucosamine 3-sulfate, 
a critical component of the sulfated proteoglycans making up the extracellular matrix proteins. 
Impaired heparan sulfate supply is associated with autistic-like behaviors in mice [38]. 
5.1.3. Autism Associated Genes with Affinity for Heparan Sulfate 
To further support the idea that a heparan sulfate deficiency in the brain is responsible for the onset 
of autism in some cases, two genes in particular, CNTNAP2 and NRXN1, which have been implicated 
in autism, encode proteins that have an affinity for heparan sulfate [70–72]. It could be that when there 
is a heparan sulfate deficiency, a less effective version of these two enzymes will decrease the efficacy 
of the heparan sulfate even further. Both CBTBAP2 (contactin associated protein-like 2) and NRXN1 
(neurexin 1) are members of the neurexin family and act as cell adhesion molecules and receptors in 
the nervous system [73]. 
5.2. Environmental Factors 
Certain genetic tendencies related to the uptake of folate and B12 increase the risk of autism 
substantially, but they do not act alone. It has been found that three genetic risk factors for autism: 
variants in catechol-O-methyl transferase (COMT), methyl tetrahydrofolate reductase (MTHFR), and 
cystathionine beta synthase (CBS) act in tandem with vitamin depletion to increase autism risk [74]. 
This is an especially important issue for the many Americans who do not meet the RDA of these vitamins.  
Increased use of sunscreen and decreased exposure to the sun may also play a role in the 
development of autism. One possible mechanism is through vitamin D, which appears to regulate the 
sodium-sulfate cotransporter NaSi-1. Mice lacking the vitamin D receptor (VDR) had NaSi-1 
expression in the kidney which was reduced by 72%, causing urinary sulfate excretion to increase by 
42% and serum sulfate concentration to decrease by 50%. In this experiment, levels of hepatic 
glutathione were reduced by 18% and skeletal sulfated proteoglycans were reduced by 45% [75]. This 
finding is especially important given the crucial role of elevated NaSi-1 expression in the mother for 
supplying sufficient amounts of sulfate to the fetus [28]. These findings are consistent with established 
findings of increased urinary sulfate excretion, decreased serum sulfate, and decreased hepatic 
glutathione concentrations in autism [7]. 
In [29] and [76], we proposed that sunlight exposure to the skin is essential not only for vitamin D3 
synthesis, but also for the synthesis of sulfate in the skin, and subsequently its combination with 
cholesterol to form cholesterol sulfate. The skin synthesizes an abundance of cholesterol sulfate, and it 
has been proposed that the skin is the major supplier of this nutrient to the tissues [77]. In fact, many 
sunscreens contain a form of retinoic acid (vitamin A) which is a known inhibitor of cholesterol sulfate 
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synthesis by squamous cells in the epidermis [78]. Cholesterol sulfate supply would likely be severely 
impaired in SLOS–over half of SLOS children are diagnosed with autism, and it is likely that impaired 
synthesis of cholesterol sulfate in the skin leads to impaired sulfate supply throughout the body. We 
propose that a similar impairment in the supply of cholesterol sulfate due to the impaired sunlight-
stimulated synthesis of sulfate in the skin may be implicated in many other cases of autism. 
In fact, there are several epidemiological clues that sunlight exposure in the mother, proposed here 
to protect against sulfate deficiency, is preventative of autism in the child. Pregnancies which occur in 
northern latitudes and births timed so that the third trimester corresponds with the late winter or early 
spring months are more likely to produce a child with autism [79]. In Nordic countries, mothers from 
foreign backgrounds, who often have darker skin, wear more conservative clothing, and consume 
reduced amounts of protective foods such as meat and fish, are more likely to have children with 
autism [80]. For example, Somalian children in Sweden have been found to have rates of autism three 
to four times higher than in the non-Somali group [81], and this is also thought to be the case for the 
Somalian population in Minnesota. 
Another increasingly common condition associated with a vitamin D deficiency [82] is diabetes, 
which has recently been shown to be the most important prenatal maternal risk factor for the 
development of autism [62]. Interestingly, vitamin D3 in the mother is also a risk factor for the 
development of preeclampsia [83], which, in turn, is also a strong risk factor for future autism in  
the fetus [84]. 
In those individuals already compromised by a reduced sulfation capacity, postnatal administration 
of acetaminophen (branded as androsten, paracetamol or tylenol) could be partially responsible for the 
rise in autism. Acetaminophen is a xenobiotic which is neutralized and metabolized by the body 
largely through sulfation, and administration of acetaminophen to rats has been shown to dramatically 
reduce sulfation capacity to the point of saturation [85]. In fact, acetaminophen use following the 
measles-mumps-rubella (MMR) vaccine in children has been shown to increase the subsequent risk for 
autism, and particularly for regressive autism [86]. In the case of children whose sulfation capacities 
are already stressed and whose central nervous systems are still in the process of developing, it is 
conceivable that administration of acetaminophen could push the system over the edge and lead to 
increased damage to the nervous system. 
Methionine synthase (MS) activity has been shown to be significantly susceptible to deactivation by 
numerous environmental toxins [87]. Both heavy metals and the ethylmercury-containing vaccine 
preservative thimerosol potently interfere with MS activation and impair folate-dependent methylation. 
Further, it has been demonstrated clinically that elevated mercury body-burden in subjects diagnosed 
with autism was associated with transsulfuration abnormalities, likely arising from increased oxidative 
stress and decreased detoxification capacity [88]. 
6. Reduced Sulfation Capacity Could Explain Other Symptoms Commonly Associated with Autism 
Sulfate and the various sulfotransferases play a major role throughout the body, and a deficiency in 
either has the potential to manifest itself in many ways beyond the neurological defects already 
described. Indeed, those with autism tend to exhibit peripheral symptoms which may also be 
associated with a reduced sulfation capacity, including gastrointestinal problems, increased androgen 
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levels, and inflammation. Indeed, these symptoms seem to occur in clusters, and abnormalities in 
folate-dependent methionine and glutathione metabolism underlying a sulfate deficit have been 
associated with gastrointestinal and immunologic dysfunction as well as previously discussed damage 
to the central nervous system [89–91]. 
6.1. Gastrointestinal Problems 
It is well known that autism is associated with various gastrointestinal symptoms [92] which have 
led many to speculate about the role of food sensitivities, dysbiotic intestinal flora, and the gut-brain 
axis in the pathology of autism [93]. The root of these digestive problems, however, may in some cases 
be reduced sulfation of the mucous proteins in the gastrointestinal tract which regulate GI tract 
function [52]. Indeed, sulfated GAGS were found to be decreased in epithelium and basement 
membrane in the colon of children diagnosed with autism [94]. Reduced sulfation of the proteins has 
been found to cause inflammation, gut dysfunction, and an increase in gut permeability [95,7], such as 
is often observed in association with autism spectrum disorders. 
6.2. Increased Androgen Levels 
The vast majority of the body’s dihydroepiandrosterone (DHEA) is stored as DHEA sulfate, the 
inactive form, but in the case of decreased sulfation seen in autism, less of the DHEA is converted into 
DHEA sulfate [51,96], and more is instead converted to testosterone through androstenedione and/or 
androstenediol. Two recent studies [97,98] reveal elevated androgen levels in subjects diagnosed with 
autism, as well as substantiating the role of impaired sulfation in inducing the observed elevated levels. 
Figure 2 illustrates the various sulfation pathways related to important metabolites, where the 
metabolites that have been identified as present in excess in autism are highlighted in orange [51]. This 
provides a compelling explanation for the increased testosterone levels seen in both males and females 
affected with ASD. In turn, the increased levels of testosterone seem to contribute to the pathology of 
ASD. Testosterone has been found to decrease cystathione β-synthase (CBS) activity, decrease GSH 
concentrations, and increase susceptibility to oxidative stress [99]. 
6.3. Inflammation 
Depleted cysteine stores, as in the case of autism, stress both sulfate and glutathione synthesis, since 
both processes compete for cysteine. As expected, this leads to low levels of glutathione (GSH) in 
autism. Low GSH results in an increase in inflammation, microglial activation, neuroinflammation, 
and expression of nitric oxide (NO) through inducible nitric oxide synthase (iNOS), all pathologies 
found in autism [100–102]. 
7. Increasing Sulfate Levels Can Help Alleviate Autistic Symptoms 
Although much of the pathology associated with autism seems, unfortunately, to be related to brain 
development during the critical period and is irreversible, an increase in sulfate levels has, in fact, been 
shown to alleviate symptoms in some children diagnosed with autism. In one study, a reduction in 
urinary sulfate excretion achieved through supplementation with molybdenum, an essential metal 
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catalyst in sulphite oxidase, correlated with improvement in autistic symptoms in patients [7]. Oral and 
transdermal glutathione supplementation, administered to children on the ASD spectrum, led to 
significant increases in plasma reduced glutathione, sulfate, cysteine, and taurine [103]. 
In the case of autism, which is hard to pin to one definite cause, it is becoming clearer that many 
different pathologies lead to the sulfate deficiency which in turn contributes to neurological damage. 
Depending on the root cause of the sulfate deficiency, different dietary supplements may be beneficial 
in treating autism. These include, specifically, the vitamins and minerals involved in the 
transsulfuration pathway (Figure 1): B12, B6, folate, magnesium and zinc. While several of these nutrients 
have been proposed for the alleviation of autism, findings have been generally inconsistent [104,105]. It is 
likely that the dysfunctional intestinal epithelium impairs uptake of these nutrients [106]. 
8. Epigenetics 
Epigenetics refers to alterations to the DNA such as methylation at CpG sites or histone acetylation, 
or the influences of silencing RNAs (siRNAs), which can either increase or decrease expression of the 
targeted gene [107]. Recent research has led to the realization that epigenetics can greatly influence 
phenotypic expression, and that the non-coding regions of the genome play an extremely important 
role in epigenetics. A key epigenetic effect that likely plays a significant if not dominant role in autism 
is global hypomethylation in the brain, which, we argue, results from impaired methyltransferase/ 
transsulfuration pathways both in the mother during gestation and in the infant postnatally. 
DNA methylation is the first layer of epigenetic effects, and environmental toxins negatively impact 
DNA methylation globally [11]. Maternal supplementation of folate, particularly in the month before 
gestation and the first two months of pregnancy, has been demonstrated to have a strong protective 
effect against autism in the fetus. This could be directly attributed to the important role that folate 
plays in the methylation pathway. However, one has to be cognizant of the effect that folate will have 
in redirecting methionine towards methylation pathways rather than towards sulfation pathways, 
thereby introducing further strain on the sulfation system under conditions of sulfur deprivation. 
Experiments on DNA hypomethylation in mouse forebrains have greatly improved our knowledge 
regarding the effect of global hypomethylation on the developing brain [108]. The experiments 
involved specifically inducing hypomethylation in excitatory neurons and astrocytes in the dorsal 
cortex and hippocampus during embryonic development. The modified mice were viable, but they 
suffered from severe degeneration of the affected brain areas. Microarray analyses revealed that 1047 
genes (6.1%) were upregulated, and 444 genes (2.6%) were downregulated. Intriguingly, the mice, 
while they lived a normal life span, exhibited severe deficits in learning and memory, associated with 
physical defects such as dystrophic neurites and an increase in dendritic branching.  
Several features of these mice correlate with known pathologies associated with autism. 
Pertubations in sodium and potassium currents were associated with impaired N-methyl-D-aspartate 
(NMDA) dependent long-term potentiation (LTP), which is also known to be abnormal in association 
with autism [109]. Sulfate deficiency likely plays a role here as well, since the glycoprotein,  
N-syndecan, enables LTP by transmitting signals received from factors binding to the attached heparan 
sulfate proteoglycans [110]. Defective syndecan-3 in mouse hippocampus leads to enhanced LTP and 
impaired memory [111]. Furthermore, DNA hypomethylation in neural stem cells triggers precocious 
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glial differentiation and activates expression of the glial cell marker, glial fibrillary acidic protein 
(Gfap) [112], which has been found to be overexpressed in association with autism [113]. This results 
in an overabundance of glial cells relative to neurons.  
Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histones, resulting in 
the inactivation of the associated genomic region. Valproic acid is an HDAC inhibitor [114] which is 
used to treat migraine headaches, cancer and mood disorders. Fetal exposure to valproic acid is 
associated with a highly increased risk to autism [109], suggesting a role for this aspect of epigenetics 
as well in autism. 
Rett syndrome is an X-linked disorder affecting females, which exhibits a behavioral manifestation 
characteristic of autism [115]. It is caused by a defect in the gene encoding methyl-CpG binding 
protein 2 (MECP2), which binds to methylated regions and activates the deacetylation of histones, 
inducing DNA inactivation. MECP2 levels are decreased in the cortex of ASD patients. Thus, impaired 
MECP2 function resembles impaired methylation in that methylated regions are not properly acted upon. 
9. Discussion 
Epidemiologic data offer strong support for the hypothesis that prenatal nutrition influences adult 
susceptibility to disease, and that this phenomenon is likely due to epigenetics [116]. The best known 
example of this involves the Dutch Hunger Winter of 1944-1945, when war-associated food scarcity 
led to widespread famine. Children born during this period were more prone to diabetes much later in 
life [117], and this is likely due to long-lasting epigenetic effects that are initiated during gestation. 
The budding field of environmental epigenomics addresses the influence that fetal nutritional status 
and exposure to toxins may have on later risk to conditions like diabetes, obesity and autism [118]. 
While the milestone of achieving a complete transcription of the genome a decade ago was heralded 
with great fanfare [119], it was sobering to recognize that the protein coding sequences, the only part 
we understood, represented a mere 2% of the genome. In the last decade, significant research dollars 
have been directed towards the goal of decoding the “epigenome,” i.e., to try to understand the crucial 
role played by the regulatory processes that dictate which genes are activated where and when [120]. 
The repeated discovery of mutations “in the junk” that influence disease risk [121] forced us to focus 
on changes in gene activation and suppression in addition to alterations in protein structure due to 
genetic mutations in coding regions. The topic of most concern to us here is the modifications to gene 
expression that occur early in development, under the influence of varied nutritional and xenobiotic 
exposure, which, we argue, can lead to a phenotypical expression that survives throughout life and 
even into subsequent generations [122]. 
One of the first identified and most studied epigenetic models is the agouti mouse, where epigenetic 
effects are readily apparent in their influence on coat color [123]. Agouti mice are born with a range of 
coat colors, from yellow to dark brown, where yellow is associated with hypomethylation in the 
promoter region of this retrotransposon during early development, and dark brown with 
hypermethylation. The yellow coloring is also associated with increased risk to obesity, diabetes,  
and tumorigenesis [124]. 
We hypothesize that the agouti gene indirectly encodes the degree of sulfate bioavailability, where 
the hypomethylated state predicts sulfate deficiency. This follows naturally from the fact that 
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methionine sits at the crossroads of the methylation and transsulfuration pathways. We further 
hypothesize, as previously proposed [29,76], that sulfate synthesis in the skin is catalyzed by sunlight. 
The mouse coat color variation is reminiscent of the pale-skinned, blond, blue-eyed Nordic phenotype 
contrasted with the dark-skinned equatorial African phenotype. Indeed, the agouti gene has been 
shown to influence the darker skin color of African Americans [125]. 
We have previously proposed that endothelial nitric oxide synthase (eNOS) is a moonlighting 
enzyme whose main product is sulfate, catalyzed by sun exposure, and, further, that the sulfate is 
combined with cholesterol to produce cholesterol sulfate in the skin, which is then transported to all 
the tissues. The enzyme’s physical structure suggests that cobalamin may facilitate the reaction, as it 
fits snugly into the heme pocket of NOS isoforms, and is known to inhibit nitric oxide synthesis [126]. 
eNOS switches to nitric oxide (and hence nitrate) synthesis following calcium entry, calmodulin 
binding and phosphorylation [127], which we view as a pathological response. eNOS is membrane-
bound in caveolae in its so-called “inactive” state, and caveolin suppresses nitric oxide synthesis. 
Nitrate can substitute for sulfate for ionic buffering in the blood, but the resulting global sulfate 
deficiency has pathological consequences [76]. Indeed, autism is associated with excess nitrite and 
nitrate in the blood [128,129]. We hypothesize that the 1,047 genes that were upregulated and the 444 
genes that were downregulated as a consequence of hypomethylation during embryogenesis [108] have 
to do with adjusting system-level parameters to account for severe sulfate deficiencies. One of those 
parameters is captured in the agouti gene, which produces a prototype more sensitive to sun exposure 
in order to increase the sunlight-catalyzed synthesis of sulfate in the skin. 
Specific experiments involving the agouti mice are compelling and supportive of our hypothesis.  
In [123], it was demonstrated that prenatal exposure to the estrogenic environmental toxin, bisphenol A 
(BPA), induced non-specific gene hypomethylation, leading to favored expression of the yellow 
phenotype. However, concurrent supplementation with folate, cobalamin, betaine and choline, 
important nutrients for the supply of methyl groups, abolished this effect. Interestingly, concurrent 
supplementation with the phytoestrogen, genistein, also abolished the effect. Genistein, a natural 
estrogen found in soy products, induces mRNA synthesis of both phenol sulfotransferase (hSULT1A1) 
and human dehydroepiandrosterone (DHEA) sulfotransferase (hSULT2A1) in the liver and colon [130]. 
DHEA sulfate (DHEAS) is found in relatively high concentrations in the blood stream and can cross 
the blood-brain barrier [131]. Furthermore, it has been shown that DHEAS, but not DHEA, inhibits 
GABAA receptors in the nervous system [132]. In fact, other sulfated steroids inhibit GABAA receptors 
as well in a non-specific way through a mechanism that depends on their generic physical properties as 
hydrophobic anions [133]. This aligns well with the observed inhibition of these receptors in 
association with autism [134]. 
SULT1A1 catalyzes the synthesis of estrone sulfate from estrone, and so would likely enable 
genistein, a natural estrogen, to transport sulfate from the gut to the nervous system. Thus, both DHEA 
sulfate and estrone sulfate could substitute for cholesterol sulfate in the blood stream, providing an 
alternative program for supplying sulfate to the nervous system. We hypothesize that dietary genistein 
provides sulfate from the digestive system, alleviating the burden on the skin to provide sulfate. BPA, 
on the other hand, induces DHEA/estrogen synthesis without supplying sulfate, which further burdens the 
sulfate system due to the need for internally-provided sulfate to transport internally synthesized estrogen. 
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While folate deficiency is recognized as a risk factor in autism, folate supplementation has met with 
varied success [135]. Interestingly, these authors propose that there may be a specific relationship 
between regressive autism and poor response to folate therapy. Furthermore, others have found an 
autoimmune reaction to folate in the central nervous system in association with autism, which prevents 
its transport across the blood brain barrier, even when levels are sufficient in the blood stream, 
associated with the so-called cerebral folate deficiency (CFD) syndrome [136]. In a study of 93 
children with autism, over 75% were found to have CFD syndrome, and 44% of the parents who were 
tested also had the condition. 
We hypothesize that all of these observations can be explained if we envision a scenario where the 
mother is supplemented with folate during gestation, but is severely deficient in supplying cholesterol 
sulfate to the fetus. The folate will redirect methionine towards methylation pathways rather than 
sulfotransferase pathways, thus further depleting the already dangerously low sulfate levels. However, 
the bioavailability of methyl groups will result in a false sense of security, whereby hypermethylated 
DNA sets up a phenotype that anticipates sulfate sufficiency. It is only after birth and continued 
subjection to factors that further deplete sulfate, such as lack of sun exposure and toxic environmental 
chemicals, that the autoimmune reaction to folate develops to spare methionine for its urgent need as a 
source of sulfate in the brain. 
This paper has perhaps produced more questions than answers, but, if our ideas are valid, they 
provide a framework for interpreting future discoveries of specific genes that are activated/inactivated 
upon hypomethylation in the brain. These are exciting times, as we are now poised to make significant 
advances in the field of epigenetics, now that a more detailed accounting of the specific effects of 
hypomethylation in different tissue types and under differing stimulating conditions is emerging [9]. If 
we can be allowed to speculate even further, it may well turn out that the genes that have been found to 
be mutated in association with autism are consequences rather than causes―that these genes are 
rendered vulnerable because of the underlying nutritional defects, and that this vulnerability is 
instantiated through epigenetics. We thus hypothesize that epigenetics is in control of evolution, and 
that hypomethylation causes certain genes to be expressed, and therefore compromised, under the very 
conditions that promote genetic mutations, such as enhanced oxidation exposure. These are then the 
genes that are more likely to experience genetic mutations under the adverse environmental conditions 
that lead to autism. Some of the random mutations may turn out to be beneficial in the context of a 
world without sunlight. 
If our hypothesis is correct, then there is some optimism that reversing the epidemic would not be 
difficult. If people can be made aware of the importance of sun exposure to the skin to health, then 
they can alter their lifestyle habits to spend additional time outdoors without sunscreen. Dietary 
changes involving increases in foods that are good sources of sulfur, such as animal-based proteins and 
cruciferous vegetables, will help to assure an adequate supply of sulfur, the substrate for sulfate 
synthesis. Foods that are rich in choline, betaine, folate, cobalamin and zinc would also be encouraged, 
as these nutrients play an important role in the methylation and sulfotransferase pathways. People 
should also be encouraged to consume cholesterol-rich foods, as this lessens the burden for cholesterol 
synthesis, and will likely increase the bioavailability of cholesterol sulfate. Finally, people should 
make a conscious effort to minimize exposure to xenobioics, which deplete sulfate supplies. Whether 
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the damage can be repaired in individuals already on the autism spectrum is doubtful, but enrichment 
along these lines would surely be of benefit to them as well. 
10. Conclusion 
In this paper, we have presented the novel hypothesis that there is a strong link between DNA 
hypomethylation and sulfate deficiency, both of which have been proposed as key factors associated 
with autism spectrum disorder. Methionine sits as the crossroads of the methylation and trans-
sulfuration pathways, and thus a deficiency in methionine supply impacts both systems. We 
hypothesize that insufficient sun exposure to the skin compromises the supply of cholesterol sulfate 
both to the fetus and to the infant postnatally, and that the concurrent exposure to environmental toxins 
further depletes sulfate and sulfur metabolites. We further hypothesize that hypomethylation during 
gestation implements a switch towards the production of nitrate rather than sulfate for ionic buffering 
in the blood stream, and that this has huge negative consequences due to the critical need for sulfate in 
neuronal maturation. Confirmation of the hypothesis awaits further studies. If our hypothesis is correct, 
then increased dietary sulfur and increased sun exposure for both the mother and the infant should be 
strongly encouraged, along with avoidance of exposure to sulfate-depleting environmental toxins. 
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